Behavioural Brain Research
August 23, 2021
Carolina Aparecida Faria Almeida, Antônio Alves Pereira-Júnior, Jéssica Gonçalves Rangel et al.
33 citations
Repeated ethanol administration to mice produced behavioral sensitization, a model of alcohol use disorder. Subsequent daily treatment with ayahuasca (1.76 mg/kg DMT) for eight days attenuated that sensitization. Ayahuasca also reduced the anxiety-like behavior triggered by ethanol withdrawal and prevented ethanol-induced changes in 5-HT1a receptor and prodynorphin levels in the hippocampus, while reducing ethanol's effects on the dynorphin/prodynorphin ratio in the striatum. The results suggest ayahuasca may modulate neuroplastic changes caused by ethanol.
Neurotoxicity research
June 7, 2025
Felype Valentim Duarte Castelhano, Carolina Aparecida de Faria Almeida, Giulia de Assis Braz et al.
3 citations
Combining ketamine with ethanol triggers greater nerve cell death than either drug alone, acting through oxidative stress and two programmed-cell-death pathways. In human neuroblastoma cells, the lowest observed adverse-effect levels were 1 mM ketamine and 100 mM ethanol. After 48 hours, the combination produced a possible synergistic increase in late apoptotic cells. Glutathione levels fell within 6 hours, and glutathione-peroxidase activity rose in all groups. Only the combination increased glutathione reductase and glutathione S-transferase activities after 3 hours, along with elevated caspase-8 and Bax expression, signaling both extrinsic and intrinsic apoptosis. The findings suggest heightened neuronal damage risk from combined use, though limitations include enzyme-activity variability, reduced sample size for some markers, and use of an immortalized cell line.
Archives of Toxicology
November 12, 2025
Gilles Salles, Carolina Aparecida de Faria Almeida, Isabella de Carvalho Alves et al.
Ayahuasca compounds N,N-dimethyltryptamine (DMT) and harmine (HRE), both alone and combined, partially protected human SH-SY5Y neuroblastoma cells from cocaine-induced toxicity. Cells exposed to cocaine with DMT and/or HRE showed increased viability compared to cocaine-only groups. Flow cytometry indicated partial to complete protection against apoptosis, and western blot revealed reduced expression of the apoptosis marker caspase-8 in co-treated cells. These findings suggest Ayahuasca-derived alkaloids merit further research for neuroprotection and treatment of substance use disorders.
Psychopharmacology
October 31, 2025
Vítor Bruno, Lídia Emmanuela Wiazowski Spelta, Matheus Lujan Pereira et al.
Ayahuasca, a brew containing DMT and β-carbolines used in indigenous rituals, has shown potential for treating substance use disorders. In C57Bl/6 mice, ayahuasca at a high dose (15 mg DMT/kg) induced rewarding effects, but these were weaker than those of cocaine. When mice were conditioned with cocaine and later treated with ayahuasca (12.5 or 15 mg DMT/kg), the brew prevented the reinstatement of cocaine-induced conditioned place preference after a cocaine challenge. The findings suggest ayahuasca may have therapeutic value for cocaine use disorder by reducing relapse to drug-seeking behavior.
Research Square
July 25, 2025
Vítor Bruno, Lídia Emmanuela Wiazowski Spelta, Matheus Lujan Pereira et al.
Ayahuasca, a psychedelic brew used in indigenous rituals, reduced the reinstatement of cocaine-induced conditioned place preference in C57Bl/6 mice, suggesting potential for treating cocaine use disorder. While ayahuasca itself produced rewarding effects at the highest dose tested (15 mg DMT/kg), these were weaker than those of cocaine (10 mg/kg). Treatment with ayahuasca (12.5 or 15 mg DMT/kg) after cocaine conditioning and before a cocaine challenge effectively prevented the reactivation of drug-associated contextual preference. The findings indicate therapeutic value for ayahuasca in cocaine use disorder, though research in humans remains limited.